Optimata, Teva deal

The companies will use Optimata's Virtual Patient technology to identify discontinued drug candidates that can be rescued or redirected for development to treat solid tumors. The predictive biosimulation technology analyzes physiological, pathological and pharmacological processes in a patient's body and predicts how patients will respond to a compound. Optimata will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. ...